Bluefin Capital Management’s Idexx Laboratories IDXX Stock Holding History

Bluefin Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,442	Closed	-$270K	–	558
2016 Q1	$270K	Buy	+3,442	New	+$248K	0.03%	256
2015 Q4	–	Sell	-5,781	Closed	-$429K	–	726
2015 Q3	$429K	Buy	+5,781	New	+$414K	0.03%	267

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Bluefin Capital Management's IDXX Position: Q2 2016 in Review

Bluefin Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2016, closing a stake of 3,442 shares — an estimated $270K sold.

Bluefin Capital Management first reported a position in IDXX in Q3 2015 and held it in 2 quarters. The position peaked at $429K in Q3 2015. 437 funds tracked by Wall St. Rank hold IDXX as of Q2 2016.

Bluefin Capital Management reported no remaining Idexx Laboratories position as of Q2 2016 after selling out during the quarter.
Bluefin Capital Management sold 3,442 Idexx Laboratories shares in Q2 2016, an estimated $270K.
Bluefin Capital Management first reported a position in Idexx Laboratories in Q3 2015 and held it in 2 quarters.
Bluefin Capital Management's Idexx Laboratories position peaked at $429K in Q3 2015.
437 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2016.

Based on Bluefin Capital Management's 13F filing for Q2 2016, filed 16 Aug 2016.